Green Chemistry in Cancer Care: Towards a Sustainable Future

Rupanshi Garg (Research Scholar)
Department of Home Science, Faculty of Arts & Social Sciences,
Swami Vivekanand Subharti University, Meerut

Dr. Nishma Singh (Associate Professor)
Department of Home Science, Faculty of Arts & Social Sciences,
Swami Vivekanand Subharti University, Meerut

ORCID ID – 0009-0005-3934-3208

Abstract

The confluence of green chemistry principles and oncology is a vital frontier in the creation of sustainable medical practices. This review discusses the ways in which green chemistry will revolutionize cancer therapeutics, ranging from drug design and synthesis to clinical delivery and waste disposal. We discuss new trends such as greener synthetic pathways for chemotherapeutic drugs, green drug delivery systems, and eco-friendly radiopharmaceuticals. The ecological impact of the pharmaceutical sector, especially oncology, calls for immediate incorporation of green chemistry principles. This article collates recent findings on greener anticancer drug synthesis, biodegradable delivery systems, and minimization of waste, and discusses implementation challenges. A framework for incorporating sustainability metrics into cancer drug development pipelines and clinical practice is proposed, highlighting that environmental responsibility and patient care complement each other rather than constitute conflicting priorities.

Keywords: Green chemistry, cancer therapeutics, sustainable pharmaceuticals, drug delivery systems, environmental toxicity, pharmaceutical waste

1. Introduction

1.1 The Environmental Cost of Cancer Care

Cancer is still among the major causes of death globally, with an estimated 19.3 million new cases and 10 million deaths in the world in 2020 (Sung et al., 2021). The pattern of treatment has changed significantly over recent decades, including chemotherapy, targeted therapies, immunotherapy, and radiotherapy. But this advancement has had severe environmental repercussions. The drug industry, especially oncology drug production, produces huge amounts of hazardous waste, uses vast amounts of solvents, and forms compounds that have persistence in the environment (Daughton & Ternes, 1999).

1.2 Green Chemistry: Principles and Promise

Green chemistry, outlined in the twelve principles by Anastas and Warner (1998), is a methodical scheme for designing chemical products and processes with an inclination towards minimizing the use and generation of hazardous substances. The principles encompass waste avoidance, atom economy, less hazardous chemical syntheses, designing safer chemicals, safer solvents and auxiliaries, energy efficiency, renewable feedstocks,

lower derivatives, catalysis, designing for degradation, real-time pollution prevention, and inherently safer chemistry.

1.3 Rationale and Scope

Use of green chemistry to cancer treatment is not only an environmental necessity but also a chance to increase drug safety, lower expenses, and increase access. This review discusses the situation on green chemistry applications in oncology at present, describes limitations of their implementation, and suggests directions toward the green future of cancer medicines.

2. Environmental Impact of Traditional Cancer Treatments

2.1 Footprint in Manufacturing

Conventional synthesis of anticancer agents frequently involves atom-economically poor multi-step reactions with heavy usage of toxic solvents and production of toxic waste. For example, extraction of paclitaxel from plant sources historically entailed harvesting Pacific yew tree bark, which caused widespread environmental destruction. The E-factor (environmental factor), or waste to product ratio, may be greater than 100 in drug manufacturing, with 100 kg of waste being produced per kilogram of active pharmaceutical ingredient (Sheldon, 2007).

2.2 Clinical Waste and Environmental Contamination

Chemotherapeutic drugs that are eliminated by patients are discharged into wastewater treatment plants, from where traditional treatment facilities are unable to recover them. Cytotoxic drugs such as cyclophosphamide, ifosfamide, and platinum complexes have been found in surface water, which can impact aquatic life and drinking water sources (Booker et al., 2014). Hospital authorities produce about 5.9 million tons of waste every year, with cancer treatment units contributing a major portion of hazardous medical waste.

2.3 Energy Consumption and Carbon Footprint

Cancer treatment facilities, especially those with radiation oncology and specialized ventilation, use a lot of energy. Carbon footprint of cancer treatment ranges from drug production to cold chain logistics to clinical administration and waste management.

3. Green Chemistry Strategies for Anticancer Drug Discovery

3.1 Green Synthesis of Chemotherapeutic Agents

3.1.1 Biocatalysis and Enzymatic Synthesis

Biocatalysis provides soft reaction conditions, high selectivity, and less waste generation. Semi-synthesis of paclitaxel from plant cell cultures grown from renewable sources through enzymatic conversions illustrates this strategy (Croteau et al., 2006). Engineered microorganisms are able to synthesize complex anticancer products such as camptothecin derivatives and vinca alkaloids, minimizing dependence on plant harvesting or aggressive chemical synthesis.

3.1.2 Continuous Flow Chemistry

Flow reactors allow very tight control over reaction conditions, enhanced heat transfer, and greater security during working with dangerous reagents. Flow chemistry has been reported to be successfully used to synthesize different anticancer agents, such as kinase inhibitors, through decreased consumption of solvents and reaction time (Gutmann et al., 2015).

3.1.3 Solvent-Free and Water-Based Synthesis

Substitution of volatile organic solvents for water or solvent-free conditions is a milestone green chemistry achievement. Routes to platinum complexes and organic anticancer agents using aqueous routes have been established, with a dramatic decrease in environmental footprint and worker exposure risk (Simon & Li, 2012).

3.2 Natural Product-Inspired Drug Discovery

Nature offers a renewable reservoir of anticancer lead compounds. About 70% of anticancer drugs launched between 1981 and 2019 were natural products or derived from natural product pharmacophores (Newman & Cragg, 2020). Green extraction methods such as supercritical CO_2 extraction, microwave-assisted extraction, and ultrasound-assisted extraction provide effective, eco-friendly means of recovering bioactive compounds from plants, marine life, and microorganisms.

3.3 Photoredox Catalysis

Photoredox catalysis, where visible light is used in place of severe reagents or heat, has proven to be a very effective green chemistry technique. This has been used for the synthesis of challenging heterocycles for anticancer drug discovery with mild conditions and good tolerance of functional groups (Prier et al., 2013).

4. Sustainable Drug Delivery Systems

4.1 Biodegradable Nanocarriers

Traditional nanocarriers usually utilize non-biodegradable polymers or metal nanoparticles that become deposited in tissues and the environment. Green chemistry principles direct development of biodegradable counterparts:

4.1.1 Natural Polymer-Based Systems

Chitosan, alginate, hyaluronic acid, and cellulose derivatives provide biocompatibility, biodegradability, and functionality for targeted delivery of drugs. These materials can be derived from renewable feedstocks using green extraction techniques and functionalized under mild conditions (Senapati et al., 2018).

4.1.2 Lipid-Based Nanocarriers

Liposomes and lipid nanoparticles that are made of biocompatible lipids achieve efficient encapsulation of drugs with reduced environmental footprint. Their building blocks naturally get degraded via metabolic processes without forming toxic byproducts.

4.2 Stimuli-Responsive Delivery Systems

Intelligent delivery systems that react to tumor microenvironment traits (pH, redox potential, enzymes) allow for controlled release of drugs, minimizing systemic toxicity and environmental pollution by drugs being excreted. They may be formulated based on biodegradable linkers and eco-friendly materials (Karimi et al., 2016).

4.3 Green Synthesis of Nanoparticles

Biological synthesis of metal nanoparticles with plant extracts, bacteria, or fungi avoids toxic reducing agents and capping agents. Gold, silver, and iron oxide nanoparticles for cancer theranostics have been obtained by successful green synthesis, which shows similar or better properties compared to conventionally synthesized particles (Dauthal & Mukhopadhyay, 2016).

5. Green Radiopharmaceuticals

5.1 Sustainable Radiosynthesis

Radiopharmaceuticals for cancer imaging and therapy are often based on organic solvents and extreme conditions. Green chemistry strategies involve:

- **Aqueous radiolabeling:** Creating water-based methods of radiolabeling with ^{18}F, ^{64}Cu, and ^{68}Ga
- **Microfluidic radiochemistry**: Minimizing waste in radiotracer manufacturing through miniaturization
- **Enzymatic radiolabeling**: Employing enzymes for site-specific radionuclide incorporation

5.2 Targeted Alpha Therapy

Alpha-emitting radionuclides (^{225}Ac, ^{213}Bi) paired with selective targeting vectors reduce radiation exposure to normal tissues and the environment. Green chemistry principles inform the creation of stable, degradable chelators and targeting moieties (Morgenstern et al., 2018).

6. Waste Reduction and Management Strategies

6.1 Design for Degradation

Incorporating designed-in degradation mechanisms in anticancer drug design guarantees that metabolites are less toxic and less persistent. Ester linkages, peptide spacers, and photodegradable units allow for controlled degradation into environmentally friendly products.

6.2 Closed-Loop Systems

Closed-loop manufacturing practices with recycling of solvents and reagents minimize waste generation. High-end filtration and purification technologies facilitate recovery of solvents with low loss of quality.

6.3 Advanced Wastewater Treatment

Oncology-specific wastewater treatment using advanced oxidation processes, membrane bioreactors, and adsorption technologies can eliminate cytotoxic compounds prior to environmental release. Point-of-use treatment systems in oncology units are an upfront strategy for the prevention of pharmaceutical contamination (Lienert et al., 2007).

6.4 Green Packaging and Distribution

Reduced packaging waste, sustainable packaging materials, and optimized cold chain logistics all lead to a reduction in overall environmental footprint. Biodegradable materials and reusable containers for drug transport reduce plastic waste.

7. Case Studies: Success Stories in Green Cancer Therapeutics

7.1 Paclitaxel: From Tree Bark to Sustainable Production

The evolution of paclitaxel production illustrates green chemistry's transformative potential. Initial isolation from Pacific yew bark was unsustainable. Subsequently developed approaches include:

- Semi-synthesis from renewable 10-deacetylbaccatin III extracted from yew needles
- Plant cell fermentation technology (Taxus cell cultures)
- Engineered E. coli and yeast strains producing paclitaxel precursors

- These approaches significantly minimized environmental impact while enhancing supply security (Malik et al., 2011).

7.2 Platinum Drugs: Greener Synthesis

Cisplatin and platinum derivatives are cancer chemotherapy workhorses. Green chemistry advancements involve:

- Water-based synthesis procedures removing dimethylformamide
- Continuous flow synthesis decreasing reaction times from hours to minutes
- Ligand exchange reactions in environmentally friendly solvents

7.3 Doxorubicin-Loaded Green Nanocarriers

Several studies prove successful encapsulation of doxorubicin in green-synthesized nanocarriers such as:

- Chitosan nanoparticles synthesized via ionic gelation
- Liposomes composed of natural lipids
- Plant extract-assisted synthesis of gold nanoparticles

They exhibit increased anticancer efficacy with decreased cardiotoxicity and environmental toxicity (Alexis et al., 2010).

8. Challenges and Barriers to Implementation

8.1 Regulatory Considerations

Regulatory systems put in place for traditional pharmaceuticals might not address adequately green chemistry advancements. Proving bioequivalence for medicines prepared by green pathways and defining standards for biodegradable drug delivery systems necessitate regulatory adaptation.

8.2 Economic Factors

Upfront investment in green chemistry technologies, employee training, and process development can be high. Nonetheless, life cycle analyses increasingly show long-term economic savings through waste disposal reduction, lowered solvent use, and enhanced yields.

8.3 Technical Challenges

Certain green chemistry strategies encounter technical restraints:

- Scalability challenges with biocatalytic process
- Restricted scope of substrates for some green reactions
- Stability with biodegradable products

8.4 Paradigm Shift Requirements

Healthcare systems traditionally prioritize efficacy and safety over environmental considerations. Integrating sustainability metrics into drug development and clinical practice requires cultural and systemic changes.

9. Future Directions and Emerging Technologies

9.1 Artificial Intelligence and Machine Learning

AI-based prediction of green synthetic pathways, determination of sustainable starting materials, and optimization of reaction conditions can expedite green chemistry implementation. Machine learning models can

be used to predict environmental fate and toxicity of drug candidates in early development (Gómez-Bombarelli et al., 2016).

9.2 Synthetic Biology

Engineered biological systems present unprecedented opportunities for sustainable production of anticancer drugs. CRISPR-based metabolic engineering allows microorganisms and plant cells to produce complex molecules with low environmental footprint.

9.3 Supramolecular Chemistry

Supramolecular drug delivery systems through self-assembly with stimuli-responsive properties without covalent modification provide a way to achieve next-generation green therapeutics using biodegradable components.

9.4 Personalized Medicine and Green Chemistry

Precision medicine strategies can decrease overall consumption of drugs by targeting therapies more precisely. Point-of-care, on-demand preparation of drugs through miniaturized green chemistry platforms could eradicate distribution waste and allow for personalized dosages.

9.5 Circular Economy in Pharmaceuticals

Implementing circular economy practices in pharmaceutical production entails designing for recyclability, utilizing industrial symbiosis where waste from one process becomes feedstock for another, and instituting drug take-back schemes.

10. Structure for Incorporating Green Chemistry into Oncology

10.1 Green Metrics for the Development of Cancer Drugs

Quantitative measures allow for evaluation and comparison of environmental footprint:

- **E-factor (Environmental factor):** kg waste/kg product
- **Process Mass Intensity (PMI):** Total mass used/mass of product
- **Atom economy:** Molecular weight of final product/molecular weight of all reactants
- **Carbon footprint:** CO_2 equivalents per dose
- **Biodegradability index:** Rate and degree of environmental degradation

10.2 Life Cycle Assessment

Detailed life cycle assessment (LCA) should quantify environmental impact from raw material extraction to manufacturing, distribution, clinical use, and waste disposal. LCA determines hotspots for improvement and facilitates data-driven decision-making.

10.3 Stakeholder Engagement

Implementation is successful only with collaboration between:

- Pharmaceutical firms and contract manufacturing organizations
- Regulatory agencies
- Healthcare professionals and institutions
- Environmental groups
- Patient advocacy organizations

- Scholarly researchers

10.4 Education and Training

Incorporating green chemistry principles into the curricula of pharmacy, medicine, and chemistry guarantees that future healthcare professionals are aware of sustainability factors. Continuing medical education among practicing clinicians and pharmacists makes clinicians and pharmacists more environmentally conscious.

11. Conclusion

Green chemistry principles have the potential to revolutionize cancer treatment, resolving ecological issues while preserving or improving therapeutic effectiveness. Advances in sustainable synthesis, biodegradable drug delivery systems, and minimization of waste show feasibility and advantages. Nevertheless, a fully sustainable future for oncology is only achievable through broader systemic transformations involving drug development, regulatory policies, clinical practice, and healthcare policy.

The incorporation of green chemistry into cancer treatment is not a trade-off between environmental responsibility and patient wellness—it's a whole-systems strategy that appreciates the intricate connection between human health and the health of our planet. Cytotoxic agents intended to destroy cancerous cells don't need to last forever in our environment. Synthetic processes shouldn't produce toxic waste greater than the weight of therapeutic products. Drug delivery systems should safely break down after they have completed their curative function.

Going forward, success will hinge on:

- Ongoing innovation in green synthetic approaches and sustainable materials
- Stringent evaluation based on standardized environmental parameters
- Collaborative cross-industry, academic, and healthcare system efforts
- Policies that encourage sustainable practices and offer incentives
- Cultural shift prioritizing long-term environmental responsibility as well as short-term therapeutic requirements

The oncology field is at a crossroads. How drug development, manufacturing methods, and clinical protocols are addressed today will decide whether or not cancer care progresses toward true sustainability or continues environmentally harmful practices. The increasing amount of research reported herein shows that green chemistry in oncology is both crucial and feasible. The challenge today is to translate scientific progress and proof-of-concept experiments into universal clinical practice.

With cancer rates still on the rise worldwide, the size of oncology's footprint will only increase unless action is taken. Green chemistry provides the tools and concepts for ensuring that advances in cancer therapy do not come at the expense of environmental degradation and patient health risks from pharmaceutical pollution. Embracing this paradigm shift is not just our obligation to the next generation but an opportunity to prove that advanced medicine and environmental awareness are compatible objectives in creating a healthier world for everyone.

References

1. Alexis, F., Rhee, J. W., Richie, J. P., Radovic-Moreno, A. F., Langer, R., & Farokhzad, O. C. (2010). New frontiers in nanotechnology for cancer treatment. *Urologic Oncology: Seminars and Original Investigations, 28*(1), 74-85.
2. Anastas, P. T., & Warner, J. C. (1998). *Green chemistry: Theory and practice*. Oxford University Press.
3. Booker, V., Halsall, C., Llewellyn, N., Johnson, A., & Williams, R. (2014). Prioritising anticancer drugs for environmental monitoring and risk assessment purposes. *Science of the Total Environment, 473*, 159-170.
4. Croteau, R., Ketchum, R. E., Long, R. M., Kaspera, R., & Wildung, M. R. (2006). Taxol biosynthesis and molecular genetics. *Phytochemistry Reviews, 5*(1), 75-97.
5. Daughton, C. G., & Ternes, T. A. (1999). Pharmaceuticals and personal care products in the environment: Agents of subtle change? *Environmental Health Perspectives, 107*(suppl 6), 907-938.
6. Dauthal, P., & Mukhopadhyay, M. (2016). Noble metal nanoparticles: Plant-mediated synthesis, mechanistic aspects of synthesis, and applications. *Industrial & Engineering Chemistry Research, 55*(36), 9557-9577.
7. Gómez-Bombarelli, R., Wei, J. N., Duvenaud, D., Hernández-Lobato, J. M., Sánchez-Lengeling, B., Sheberla, D., ... & Aspuru-Guzik, A. (2016). Automatic chemical design using a data-driven continuous representation of molecules. *ACS Central Science, 4*(2), 268-276.
8. Gutmann, B., Cantillo, D., & Kappe, C. O. (2015). Continuous-flow technology—A tool for the safe manufacturing of active pharmaceutical ingredients. *Angewandte Chemie International Edition, 54*(23), 6688-6728.
9. Karimi, M., Ghasemi, A., Sahandi Zangabad, P., Rahighi, R., Moosavi Basri, S. M., Mirshekari, H., ... & Hamblin, M. R. (2016). Smart micro/nanoparticles in stimulus-responsive drug/gene delivery systems. *Chemical Society Reviews, 45*(5), 1457-1501.
10. Lienert, J., Bürki, T., & Escher, B. I. (2007). Reducing micropollutants with source control: Substance flow analysis of 212 pharmaceuticals in faeces and urine. *Water Science and Technology, 56*(5), 87-96.
11. Malik, S., Cusidó, R. M., Mirjalili, M. H., Moyano, E., Palazón, J., & Bonfill, M. (2011). Production of the anticancer drug taxol in Taxus baccata suspension cultures: A review. *Process Biochemistry, 46*(1), 23-34.
12. Morgenstern, A., Apostolidis, C., & Bruchertseifer, F. (2018). Supply and clinical application of actinium-225 and bismuth-213. *Seminars in Nuclear Medicine, 48*(2), 133-140.
13. Newman, D. J., & Cragg, G. M. (2020). Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. *Journal of Natural Products, 83*(3), 770-803.
14. Prier, C. K., Rankic, D. A., & MacMillan, D. W. (2013). Visible light photoredox catalysis with transition metal complexes: Applications in organic synthesis. *Chemical Reviews, 113*(7), 5322-5363.
15. Senapati, S., Mahanta, A. K., Kumar, S., & Maiti, P. (2018). Controlled drug delivery vehicles for cancer treatment and their performance. *Signal Transduction and Targeted Therapy, 3*(1), 1-19.
16. Sheldon, R. A. (2007). The E factor: Fifteen years on. *Green Chemistry, 9*(12), 1273-1283.
17. Simon, M. O., & Li, C. J. (2012). Green chemistry oriented organic synthesis in water. *Chemical Society Reviews, 41*(4), 1415-1427.
18. Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians, 71*(3), 209-249.